Lacosamide Fresenius Kabi

Lacosamide, the active ingredient in Lacosamide Fresenius Kabi, is an anticonvulsant presented as an injectable solution for intravenous use. It treats partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lacosamide is an antiepileptic drug that acts on neuronal sodium channels to control seizure activity.

Partial‑onset seizures: Reduces seizure frequency in patients with focal epilepsy. Epilepsy (adjunct therapy): Provides additional seizure control when added to existing regimens. Refractory focal epilepsy: Offers an alternative mechanism for patients not responding to other antiepileptics.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue

Serious or Rare Side Effects: - Cardiac arrhythmia (including atrioventricular block) - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Respiratory depression

Before initiating therapy, consider the following safety measures.

Renal impairment: Adjust monitoring and dosing as needed. Hepatic impairment: Use with caution and monitor liver function. Concomitant CNS depressants: Observe for enhanced sedation. Cardiac history: Perform ECG monitoring for conduction abnormalities. Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus. Store at ambient temperature: Keep in the original packaging, protect from moisture and light.

Lacosamide can interact with several drug classes; awareness helps mitigate risks.

Major Interactions (Avoid): - Class I antiarrhythmics: May increase risk of cardiac conduction disturbances. - Strong CYP3A4 inhibitors (e.g., ketoconazole): May raise lacosamide plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin): May reduce lacosamide efficacy.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs: May require dose adjustments. - Alcohol: May enhance central nervous system depression. - Tricyclic antidepressants: May increase dizziness and sedation.